RegisterLogin

Navitoclax

CAT: 0804-HY-10087-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-10087-01Size:5 mg
Selected
PRICE
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Navitoclax (ABT-263) is a potent and orally active Bcl-2 family protein inhibitor that binds to multiple anti-apoptotic Bcl-2 family proteins, such as Bcl-xL, Bcl-2 and Bcl-w, with a Ki of less than 1 nM[1].
CAS Number
[923564-51-6]
Product Name Alternative
ABT-263
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Bcl-2 Family
Type
Reference compound
Related Pathways
Apoptosis
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/navitoclax.html
Purity
99.97
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=S(C1=CC(S(NC(C2=CC=C(N3CCN(CC4=C(CCC(C)(C4)C)C5=CC=C(Cl)C=C5)CC3)C=C2)=O)(=O)=O)=CC=C1N[C@H](CCN6CCOCC6)CSC7=CC=CC=C7)(C(F)(F)F)=O
Molecular Formula
C47H55ClF3N5O6S3
Molecular Weight
974.61
Precautions
H302, H315, H319, H335
References & Citations
[1]Lock R1, et al. Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008 Jun;50 (6) :1181-1189.|[2]Wong M, et al. Navitoclax (ABT-263) reduces Bcl-x (L) -mediated chemoresistance in ovarian cancer models.Mol Cancer Ther. 2012 Apr;11 (4) :1026-1035.|[3]Chen J, et al. The Bcl-2/Bcl-X (L) /Bcl-w inhibitor, navitoclax, enhances the activity of chemotherapeutic agents in vitro and in vivo. Mol Cancer Ther. 2011 Dec;10 (12) :2340-9.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 3
Isoform
Bcl-2; Bcl-W; Bcl-xL

Related Products

CatalogName

Alternative Products

CatalogName
MBS3606608-01Navitoclax
MBS3613628-01Navitoclax-piperazine
T71456-01Navitoclax dihydrochloride
A3007-50ABT-263 (Navitoclax)
285063-01Navitoclax (ABT 263)
C07422-01Navitoclax (ABT-263)

Popular Products